Separately, Oppenheimer started coverage on Mustang Bio in a report on Wednesday. They issued an outperform rating and a $18.00 target price for the company.
Mustang Bio (MBIO) traded up $0.51 during trading on Thursday, reaching $11.44. The company’s stock had a trading volume of 84,200 shares, compared to its average volume of 79,089. Mustang Bio has a 12 month low of $8.06 and a 12 month high of $13.35.
WARNING: This piece was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/12/22/mustang-bio-mbio-receives-new-coverage-from-analysts-at-cibc-3.html.
About Mustang Bio
Mustang Bio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.